Dr. Martens (LON:DOCS) Earns Buy Rating from Berenberg Bank

Dr. Martens (LON:DOCS)‘s stock had its “buy” rating reiterated by stock analysts at Berenberg Bank in a research report issued on Friday, London Stock Exchange reports. They currently have a GBX 110 target price on the stock. Berenberg Bank’s price objective indicates a potential upside of 58.73% from the stock’s previous close.

Dr. Martens Stock Up 2.2%

DOCS opened at GBX 69.30 on Friday. Dr. Martens has a fifty-two week low of GBX 59.15 and a fifty-two week high of GBX 97.05. The business has a 50-day moving average of GBX 74.43 and a 200-day moving average of GBX 70.86. The company has a debt-to-equity ratio of 108.85, a current ratio of 2.61 and a quick ratio of 1.13. The company has a market capitalization of £663.32 million, a PE ratio of 28.88, a price-to-earnings-growth ratio of 6.40 and a beta of 0.26.

About Dr. Martens

Dr. Martens is an iconic British footwear brand founded in Northamptonshire, England. Its first silhouette, the 1460 boot – named after the date it was produced – rolled off the production line on 1st April 1960. Originally chosen by workers for their air-cushioned comfort and durability, “Docs” or “DM’s” were later adopted by musicians and subcultural pioneers who took them from the street to the global stage.

Over six decades later, Dr. Martens operates in more than 60 countries and employs around 3,600 people.